LPGAT1 and demyelinating disease: However, changes in LPGAT1 and LIPC, which act only on LPC 18:1 but not LPC 18:0, alone can account for the observed deficiency or absence of LPC 18:1, thus suggesting the importance of lipid metabolism in demyelinating disease pathology.